TetraLogic Pharma (OTC:TLOG) Stock, Quote.Headers.trade-ideas

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.

News

Intraday Update

Markets

Movers

Trading Ideas

ABMBF

AGYS

AJRD

AKRO

AMRK

ANIK

APPN

ARCE

ATEC

ATLC

AURI

AVDR

AVLR

AZPN

BLDR

BMCH

CABGY

CABJF

CAFI

CAHPF

CASY

CDLX

CECO

CEVA

CHPGF

CIBEY

CLSI

CNMD

CNNE

CSGS

CWST

CYRX

CYTK

DCGD

ECNCF

EIFZF

EMLAF

EMRAF

ENPH

ESLT

EVRG

FBPRM

FIVN

FTDR

GGDVY

GLDLF

GROW

HEI-A

HPGLY

HUBS

IBIDF

INXN

IOTS

IPHI

IRET

ITRI

JRVR

JUBPF

LZAGY

MAIFF

MELI

Stocks That Set New 52-Week Highs Thursday

Movers & Shakers

BBBY

TLOG

WERN

Worst Performing Industries For June 21, 2016

Health Care

General

Here&#39;s Why Tetralogic Pharmaceuticals Is Down 70%

TETRALOGIC PHARMS CORP by TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corp

AACAF

AACAY

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

AAVVF

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AERG

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

ALTERNATE HEALTH CORP ORD by Alternate Health Corp.

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALFVY

ALIAF

ALIF

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLVF

ALMTF

ALPMY

ALSMY

ALVOF

ALYI

AMADY

AMAZ

AMBBY

AMIGY

AMKAF

AMKBF

AMKBY

AMLZF

AMMX

AMRQQ

AMXEF

ANEWF

ANGPY

ANPDF

ANPDY

ANSLY

ANTH

ANACONDA MINING INC by Anaconda Mining Inc.

ANXGF

Australia and New Zealand Banking Group Limited

ANZBY

ANZLY

AOIFF

AOMFF

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

APELY

APHD

APMCF

AQARF

ARAFF

ARESF

ARGKF

ARKAY

ARNGF

ARREF

ARRRF

Stocks That Hit 52-Week Highs On Tuesday

CLNXF

DFIFF

GLGDF

TetraLogic Agrees To Sell Assets To Medivir And Delisting Of Common Stock

TetraLogic Pharmaceuticals Halted; Pending News

TetraLogic Pharma Shares Halted News Pending

The Dow rose 0.12 percent to 17,827.03, while the NASDAQ composite index climbed 0.11 percent to 4,842.60. The broader Standard &amp; Poor&#39;s 500 index gained 0.15 percent to 2,086.29.

	The worst performing industries in the market today are:
<ul>
<li>
		Home Furnishing Stores: This industry slipped 1.5 percent by 11:00 am. The worst stock within the industry was Bed Bath &amp; Beyond Inc. (NASDAQ: <a class="ticker" href="/stock/bbby#NASDAQ">BBBY</a>), which fell 1.8 percent. Bed Bath &amp; Beyond is expected to post quarterly earnings on June 22, 2016.</li>
<li>
		Movie Production, Theaters: This industry declined 1.3 percent by 11:00 am with Lions Gate Entertainment Corp. (USA) (NYSE: <a class="ticker" href="/stock/lgf#NYSE">LGF</a>) moving down 2.5 percent. On Monday, Lionsgate announced a quarterly cash dividend of $0.09 per share.</li>
<li>
		Trucking: This industry fell 1.2 percent by 11:00 am ET. Werner Enterprises, Inc. (NASDAQ: <a class="ticker" href="/stock/wern#NASDAQ">WERN</a>) shares dropped 8 percent in today&#39;s trading. Werner issued a weak earnings forecast for the second quarter.</li>
<li>
		Biotechnology: The industry dropped 1 percent by 11:00 am. The worst performer in this industry was Tetralogic Pharmaceuticals Corp (NASDAQ: <a class="ticker" href="/stock/tlog#NASDAQ">TLOG</a>), which declined 17 percent.</li>
</ul>

Management

Tetralogic Pharma Says CFO/Treasurer Pete Meyers To Step Down April 30 2016, Pat Hutchinson To Be SVP, Finance, As CFO & Treasurer Of Co

Shares of Tetralogic Pharmaceuticals Corp (NASDAQ: <a class="ticker" href="/stock/tlog#NASDAQ">TLOG</a>), a clinical-stage biopharmaceutical company, plunged more than 75 percent after Wednesday&#39;s market close.

	Tetralogic <a href="http://www.globenewswire.com/news-release/2016/01/06/799975/0/en/TetraLogic-Pharmaceuticals-Announces-Data-on-Lead-Clinical-Programs.html">reported</a> that a placebo controlled Phase 2 study of <a href="http://tetralogicpharma.com/birinapant/">birinapant</a> co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes (MDS), birinapant did not demonstrate any clinical benefit over placebo on the primary endpoint of response rate after four months of therapy and met the bounds for futility.

	Tetralogic also stated that it will terminate its clinical study and the company will explore strategic alternatives.

	&quot;Whilst the results of the birinapant study in MDS are disappointing, the results we achieved with SHAPE provide an interesting product profile with activity observed on both the CAILS and mSWAT endpoints and the potential to reduce pruritus, one of the more difficult symptoms to treat in CTCL,&quot; said J. Kevin Buchi, TetraLogic CEO.

	The stock traded recently at $1.20, down 70 percent in Thursday&#39;s pre-market session.

Here's Why Tetralogic Pharmaceuticals Is Down 70%

TetraLogic Pharma Shares Continue To Fall After Hours, Down 70% Following Discontinued Phase II Trial

UPDATE: TetraLogic Pharmaceuticals birinapant Did Not Demonstrate Clinical Benefit Over Placebon ON Primary Endpoint, Study Will Be Terminated

TetraLogic Pharmaceuticals Corporation (Nasdaq: <a class="ticker" href="/stock/tlog#Nasdaq">TLOG</a>), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced the results of the interim analyses of two clinical studies. 
In a placebo controlled Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes (MDS), birinapant did not demonstrate any clinical benefit over placebo on the primary endpoint of response rate after four months of therapy and met the bounds for futility. This interim analysis included the first 62 patients randomized in the trial. This study will now be terminated.
TetraLogic has undertaken an interim analysis of a randomized Phase 2 clinical study of SHAPE, the company's proprietary topical HDAC inhibitor. The clinical trial was designed to investigate the safety and efficacy of three different dosing regimens of SHAPE in patients suffering from earlier stage cutaneous T-cell lymphoma (CTCL). All patients in the study had received prior therapy either in the form of topical steroids, UV light therapy, topical nitrogen mustard, or some other agent. Twenty-eight of 34 patients were evaluable for response at the 6 month time point. After six months of treatment, 8 of 34 patients exhibited a response to treatment as assessed by CAILS, the primary endpoint, and a further 18 had stable disease. Using the mSWAT, a secondary endpoint in the study, 11 of 34 patients responded and a further 14 patients had stable disease at the 6 month endpoint. 
SHAPE also showed improvement in pruritus (itch), a significant symptom associated with CTCL. Thirty-eight percent of patients demonstrated a clinically meaningful decrease in pruritus during the study as measured by a Visual Analog Scale. The drug was well tolerated by patients in the study. The 60 patient study is now fully enrolled, and the company expects that final results will be available in mid-2016.
"Whilst the results of the birinapant study in MDS are disappointing, the results we achieved with SHAPE provide an interesting product profile with activity observed on both the CAILS and mSWAT endpoints and the potential to reduce pruritus, one of the more difficult symptoms to treat in CTCL," said J. Kevin Buchi, TetraLogic CEO. "We are exploring our strategic alternatives based upon the results seen in these studies."

TetraLogic Pharmaceuticals Says Birinapant Shows No Activity in Randomized Phase 2 MDS Study; SHAPE Shows Clinical Benefit in Randomized Phase 2 CTCL Study

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

TetraLogic Pharma

TetraLogic Pharma (TLOG) Forecast

TetraLogic Pharma (OTC:TLOG) Stock, Quote.Headers.trade-ideas